Corcept Therapeutics Incorporated
CORT
Helyezés a részvények között
#1691
Corcept Therapeutics Incorporated, founded in 1998 and headquartered in Menlo... Corcept Therapeutics Incorporated, founded in 1998 and headquartered in Menlo Park, California, is a pharmaceutical firm dedicated to the discovery, development, and commercialization of treatments for serious metabolic, oncological, and neuropsychiatric disorders across the United States. Its primary commercial offering is Korlym (mifepristone) tablets, an oral medication taken once daily. Korlym is prescribed for adult patients diagnosed with endogenous Cushing's syndrome who suffer from hyperglycemia due to hypercortisolism, particularly those with type 2 diabetes or glucose intolerance, and for whom surgical options have either failed or are not viable. The company's development pipeline is robust, featuring relacorilant, which is being advanced for Cushing's syndrome. It is also investigating a combination of relacorilant with nab-paclitaxel; this pairing has concluded Phase II clinical trials for advanced ovarian tumors and is additionally being studied for conditions involving cortisol excess. Furthermore, Corcept is developing distinct selective cortisol modulators for specific indications such as metastatic castration-resistant prostate cancer and antipsychotic-induced weight gain, alongside research into FKBP5 gene expression assays.
Részvényárfolyam
$116.39
Utolsó szinkronizálás: 2026-10-21
Piaci kapitalizáció
$12.58B
Változás (1 nap)
-0.05%
Változás (1 év)
58.03%
Ország
US
Kereskedés Corcept Therapeutics Incorporated (CORT)
Kategória
Healthcare
Corcept Therapeutics Incorporated (CORT) részvényárfolyamának története
Legmagasabb napi záróár: $116.99 ekkor: 2026-10-01
Legalacsonyabb napi záróár: $11.30 ekkor: 2004-04-01
Legalacsonyabb napi záróár: $11.30 ekkor: 2004-04-01
Corcept Therapeutics Incorporated részvényárfolyamának története 2004 és 2026 között
Éves részvényárfolyam teljesítmény
| Év | Teljesítmény |
|---|---|
| 2026 (TTM) | -9.40% |
| 2025 | 45.40% |
| 2024 | 87.74% |
| 2023 | 37.96% |
| 2022 | 8.70% |
| 2021 | -22.54% |
| 2020 | 97.11% |
| 2019 | -8.02% |
| 2018 | -18.04% |
| 2017 | 113.00% |
| 2016 | 61.25% |
| 2015 | 59.73% |
| 2014 | 23.32% |
| 2013 | 64.30% |
| 2012 | -54.17% |
| 2011 | -17.98% |
| 2010 | 63.22% |
| 2009 | 127.09% |
| 2008 | -61.78% |
| 2007 | 209.70% |
| 2006 | -77.05% |
| 2005 | -25.76% |
| 2004 | 0.00% |
Hasonló cégek vagy versenytársak részvényárai
| Vállalat | Részvényár | Változás 1év% | Ország |
|---|---|---|---|
| $62.20 | 68.82% |
US
|
|
| $45.44 | 35.30% |
SE
|
|
| $172.38 | 24.64% |
FR
|
|
| $59.46 | -0.57% |
IT
|
|
| $0.63 | -31.50% |
HK
|
